OnDemand Wills Eye Hospital Ophthalmology Review Course 2024

Registration for the 2024 OnDemand Review Course is now closed. If you are looking for the 2025 OnDemand Review Course, this registration will be posted to Cloud-CME on Monday February 3rd under OnDemand Courses with a link on the homepage banner. Thank you!

All video content will be unlocked March 1st, 2024 through February 28th, 2025.

The premier Ophthalmic review course nationally and internationally, the Wills Eye Hospital Review Course features world-renowned experts providing a comprehensive and intensive review of the basic principles in each subspecialty of ophthalmology along with recent advances. Course participants will be well prepared to sit for the OKAPS, ABO or MOC exams. The course is also an excellent refresher for practicing ophthalmologists. the course will be delivered virtually as a self-guided on-demand learning activity.

Guest Faculty

David L. Guyton, MD, Professor of Ophthalmology,
The Wilmer Ophthalmological Institute, Johns Hopkins University,
Baltimore, Maryland

Kristina Irsch, PhD, Assistant Professor of Ophthalmology,
The Wilmer Ophthalmological Institute, Johns Hopkins University,
Baltimore, Maryland

Peter J. Savino, MD, Clinical Professor of Ophthalmology & Neurosciences, Shiley Eye Institute, UC San Diego Health

Hermann D. Schubert, MD, Professor of Clinical Ophthalmology
and Pathology, Columbia University, New York, New York

Wills Eye Hospital Faculty

Jurij R. Bilyk, MD, Attending Surgeon, Oculoplastic Service

Jacqueline Carrasco, MD, Attending Surgeon, Oculoplastic & Orbital Surgery

Ralph C. Eagle, Jr., MD, Service Chief, Department of Pathology

Mitchell S. Fineman, MD, Attending Surgeon, Retina Service

Sunir J. Garg, MD, Attending Surgeon, Retina Service

Kristin M. Hammersmith, MD, Attending Surgeon, Cornea Service

Daniel Lee, MD, Attending Surgeon, Glaucoma Service

Jonathan S. Myers, MD, Service Chief, Glaucoma Service

Christopher J. Rapuano, MD, Service Chief, Cornea Service

Bruce M. Schnall, MD, Attending Surgeon, Adult and Pediatric Strabismus

Carol L. Shields, MD, Service Chief, Oncology Service

James F. Vander, MD, Attending Surgeon, Retina Service

Barry N. Wasserman, MD, Attending Surgeon, Pediatric Ophthalmology Service


This activity has been approved for AMA PRA Category 1 Credit™

1. Provide a comprehensive review of topics in ophthalmology including: Optics and Refraction; Antomy and Embryology; Retina and Vitreous; Ocular Pathology; Orbit, Eyelid and Lacrimal System; Pharmacology and Therapeutics; Ocular Tumors; Neuro-Ophthalmology; Corneal and External Diseases; Uveitis and AIDS; Glaucoma; Pediatric Ophthalmology and Strabismus; CT and MRI Imaging of Eye and Orbit.
2. Better understand the pathophysiology of most ophthalmic disease.
3. Perform appropriate diagnostic tests and differential diagnosis for most ophthalmic diseases.

AMA PRA Statement
Wills Eye Hospital designates this Enduring Material for a maximum of 61.75 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Mitigation of Relevant Financial Relationships

In compliance with the Standards for Integrity and Independence in Accredited Continuing Education set by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of Wills Eye Hospital that the information presented at CME activities will be commercially unbiased and based upon clinical and scientific evidence. To help participants make judgments about the presence of commercial bias, Wills Eye Hospital provides information that all individuals in a position to control the content of a CME activity (including faculty, planners, reviewers or others) have disclosed about all financial relationships they have with ineligible companies. All relevant financial relationships have been mitigated.

Ineligible companies are companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company. The CME activity staff at Wills Eye Hospital report no financial relationships with ineligible companies.

Member Information

Role in activity

Nature of Relationship(s) / Name of Ineligible Company(s)

Jurij R. Bilyk, MD
Wills Eye Hospital

Faculty

Nothing to disclose

Jackie R. Carrasco, MD
Wills

Faculty

Speakers Bureau-Horizon Therapeutics

Mitchell S. Fineman, MD
MidAtlantic Retina, The Retina Service of Wills Eye Hospital

Faculty

Nothing to disclose

Sunir J. Garg, MD
MidAtlantic Retina, The Retina Service of Wills Eye Hospital

Faculty

Consulting Fee-Bausch + Lomb|Consulting Fee-Johnson & Johnson|Consulting Fee-Allergan|Consulting Fee-Boehringer Ingelheim|Consulting Fee-Apellis Pharmaceuticals|Consulting Fee-Merck|Grant or research support-Allergan|Grant or research support-Boehringer Ingelheim|Grant or research support-Genentech|Grant or research support-Regeneron|Grant or research support-Apellis Pharmaceuticals|Grant or research support-NGM Bio

David L. Guyton, MD
Wilmer Eye Institute, Johns Hopkins University School of Medicine

Faculty

Grant or research support-Rebion, Inc (STTR grant from NIH)

Kristin M. Hammersmith, MD
University of Pennsylvania

Faculty

Nothing to disclose

Kristina Irsch, PhD
Vision Insitute - CNRS & Wilmer Eye Insitute - Johns Hopkins University

Faculty

Nothing to disclose

Daniel Lee, MD

Faculty

Grant or research support-Allergan (Relationship has ended)|Grant or research support-Equinox (Relationship has ended)|Grant or research support-Glaukos Corporation (Relationship has ended)|Grant or research support-Mati (Relationship has ended)|Grant or research support-New World Medical (Relationship has ended)|Grant or research support-Nicox (Relationship has ended)|Grant or research support-Olleyes (Relationship has ended)|Consulting Fee-Quidel (Relationship has ended)|Grant or research support-Santen Pharmaceuticals (Relationship has ended)|Grant or research support-Ocular Therapeutix (Relationship has ended)

Shaunna Lee, MS
Wills Eye Hospital

Faculty

Private Corp Stock-Acucela

Jonathan S. Myers, MD
Wills Eye Hospital

Faculty

Stocks or stock options, excluding diversified mutual funds-Avisi|Stocks or stock options, excluding diversified mutual funds-Olleyes|Grant or research support-Allergan (Relationship has ended)|Grant or research support-Glaukos Corporation|Grant or research support-Nicox (Relationship has ended)|Grant or research support-Santen Pharmaceuticals (Relationship has ended)|Grant or research support-Guardian|Grant or research support-Laboratories Thea Inc|Grant or research support-Ocular Therapeutix (Relationship has ended)

Christopher J. Rapuano, MD
Wills Eye Hospital

Faculty

Consulting Fee-Bio-Tissue|Consulting Fee-Dompé |Consulting Fee-Glaukos Corporation|Consulting Fee-Oyster Point Pharmaceuticals|Consulting Fee-Sight Sciences|Consulting Fee-TearLab|Honoraria-Dompé |Stocks or stock options, excluding diversified mutual funds-Fount Bio|Stocks or stock options, excluding diversified mutual funds-RPS|Consulting Fee-Avellino|Consulting Fee-Baxis|Consulting Fee-Emmecell|Consulting Fee-Kala Pharmaceuticals

Peter J Savino, MD
Shiley Eye Institute UCSD

Faculty

Nothing to disclose

Bruce M. Schnall, MD
Wills Eye Hospital

Faculty

Nothing to disclose

Hermann D. Schubert, MD
Edward S. Harkness Eye Institute, Columbia University

Faculty

Nothing to disclose

Carol L. Shields, MD
Shields and Shields MD PC

Faculty

Nothing to disclose

James F. Vander, MD
MidAtlantic Retina, The Retina Service of Wills Eye Hospital

Faculty

Nothing to disclose

Barry N. Wasserman, MD
BARRY N WASSERMAN MD LLC

Faculty

Nothing to disclose

Ralph C. Eagle Jr., MD
Director
Wills Eye Hospital

Faculty, Planner

Stocks or stock options, excluding diversified mutual funds-Merck